This is the first of many launches. I don't think anyone expects $50m in sales, but it shows progress and lays out a commercial path for new variations of stevia.
I have followed SANW for several years, and I thought an article published yesterday was very interesting. It looked at SANW failure to produce stevia and how the company's wording has changed in the process. It is a great read and mentions STVF as a company that is ahead of SANW with a commercial launch. You can read the article on SANW ticker page
Bears screaming "scam". They'll probably say the same once STVF launches their first product, and has 10 more on the market.
The evolution of healthy foods by Robert Brooke is one reason the stock is rallying. Yet another dimension to the sugar debates that have sent STVF higher by almost 100% in the last few weeks. I think it's going even higher.
We all know that STVF has traded from $0.3 to $0.5 for two reasons: Sugar being called next tobacco with a lot of negative publicity and also the pending launch of its first commercial product.
STVF wants to become the first fully integrated stevia company, meaning there is much more to the business than just one product. Hopefully, STVF has 100 products in the next 10 years, and partnerships with many if not all major food and drink companies.
But let's say sales of this first product are strong, and by strong I mean $5 million annually. What does that do to the perception of this company, and the way people view its future. Personally, I consider $2 million a success, but more-so I am excited to see how the company launches the product and what it tells us about the future.
INO would get a small but known piece. The MCC indication alone has no treatment and peak sales potential of $300 million. That's massive to ONCS but very small compared to INO's market cap. ONCS presents far more upside with limited risk IMO
Article on Yahoo
If and when Stevia First launches their first product, naysayers won't know what to say. They've been screaming for months that STVF will never have a commercial product. Looks like STVF is close to revenue now.
Sentiment: Strong Buy
What company with a newly launched product ever sees improvements on their bottom line. The goal right now is revenue generation. STVF is making the right moves to secure its future. Once sales are created the company will see a new base of investors looking for a play on stevia growth.
It seems like STVF is close to producing revenue, with distribution channel in place. I'm looking forward to the next year, especially with more focus on the health effects of sugar. It seems that STVF could be a dark horse to trade higher. We'll see.
Sentiment: Strong Buy
It's really quite simple, look at the chart: NBS has consistently fallen following the public offering. NeoStem introduced a lot of new shares and it has temporarily created more sellers than buyers. This often happens after public offerings, but given the degree at which it has fallen, and its resiliency at this level, NBS could very well reverse very quickly. Now, there are likely more buyers then sellers, and NBS will rise with the multitude of catalysts it has working in its favor.
NBS falls 6% despite below average volume. For those of you who don't know, volume is a sign of conviction. With such low volume we can be certain that losses are not sustainable.